Published on 22/12/2025
How Digital Health and eConsent Are Transforming Clinical Trials in China
Introduction
The adoption of digital health technologies and electronic informed consent (eConsent) is reshaping the clinical trial landscape in China. With the National Medical Products Administration (NMPA) modernizing regulations and aligning with global best practices, sponsors now have more flexibility to implement decentralized and technology-enabled trial models. These innovations not only improve patient recruitment and retention but also enhance transparency, data integrity, and regulatory compliance. For China—a country with diverse patient populations and vast geographic disparities—digital health solutions hold particular promise in bridging gaps between Tier-1 urban hospitals and underrepresented rural communities. This article explores how digital health and eConsent are evolving in Chinese clinical trials, highlighting regulatory expectations, operational insights, and challenges sponsors must address.
Background and Regulatory Framework
Evolution of eConsent in China
Informed consent has long been a focus of China’s Good Clinical Practice (GCP) framework. Traditionally paper-based, the process has faced challenges in ensuring comprehension and accessibility, particularly in rural regions. In 2020, the NMPA issued guidance allowing electronic informed consent under strict conditions, provided that systems ensure authenticity, audit trails, and patient understanding.
Regulatory Support for Digital Health
China’s participation in the
Case Example: COVID-19 Decentralized Trials
During the COVID-19 pandemic, eConsent and telemedicine platforms enabled continuity of several multinational trials in China. These experiences validated the feasibility of digital health tools in a regulatory-compliant manner, paving the way for broader adoption post-pandemic.
Core Clinical Trial Insights
Benefits of eConsent
eConsent enhances patient comprehension through multimedia tools such as videos, graphics, and interactive quizzes. It improves transparency by ensuring standardized explanations of risks and benefits. Audit trails provide regulators with verifiable records of consent, strengthening compliance. In rural areas, eConsent can help overcome literacy barriers by offering audio and visual explanations.
Challenges in Implementation
Despite its benefits, eConsent faces hurdles:
✔️ Limited digital literacy among elderly patients
✔️ Infrastructure gaps in Tier-2 and rural hospitals
✔️ Concerns about data privacy under China’s Personal Information Protection Law (PIPL)
✔️ Resistance from some ethics committees unfamiliar with digital systems
Sponsors must address these issues through training, capacity building, and patient-friendly system design.
Integration of Wearables and Mobile Health
Wearable devices and mobile health apps are increasingly used for remote monitoring of oncology, cardiovascular, and metabolic disease trials. These tools improve data collection but must be validated and approved by ethics committees. Data from wearables must also comply with China’s localization and cybersecurity laws.
Electronic Data Capture and eSource
Chinese sites are adopting EDC and eSource platforms to replace paper records, improving data integrity and efficiency. The NMPA requires that these systems include audit trails, validation, and secure storage. Sponsors must ensure system validation according to international standards like 21 CFR Part 11.
Impact on Patient Recruitment and Retention
Digital health tools can expand patient recruitment beyond Tier-1 hospitals, engaging participants in provincial regions through telemedicine consultations and mobile apps. By reducing travel burdens, these tools improve patient retention, a common challenge in long-term trials.
Ethics Committee Oversight
Ethics committees in China must approve all eConsent and digital health tools used in trials. Committees increasingly request demonstrations of system functionality, validation reports, and multilingual patient interfaces. This oversight ensures compliance but can extend review timelines if documentation is incomplete.
Best Practices & Preventive Measures
Sponsors should pilot eConsent and digital platforms in Tier-1 hospitals before scaling to Tier-2 sites. Early engagement with ethics committees and patient advocacy groups can address trust and usability concerns. CROs play a critical role in training site staff and monitoring compliance. SOPs should cover digital tool validation, data privacy, and audit readiness.
Scientific & Regulatory Evidence
NMPA’s guidance on eConsent reflects ICH E6(R2) principles and aligns with FDA’s electronic consent guidelines. WHO GCP also emphasizes participant comprehension and consent documentation, both supported by digital tools. Evidence from COVID-19 decentralized trials demonstrates that digital solutions can meet compliance requirements while improving trial continuity.
Special Considerations
Digital health adoption varies across China. Urban Tier-1 hospitals often have robust IT systems, while rural areas face bandwidth and literacy challenges. Sponsors must adapt tools for diverse populations, ensuring interfaces are multilingual, culturally sensitive, and accessible to patients with limited digital literacy.
When Sponsors Should Seek Regulatory Advice
Sponsors should seek NMPA advice when implementing eConsent, wearables, or other novel digital platforms in trials. Pre-submission meetings help clarify expectations for system validation, data privacy compliance, and ethics review requirements. Sponsors should also consult regulators when planning decentralized or hybrid trial models.
Case Studies
Case Study 1: Oncology Trial Using eConsent
A multinational oncology trial piloted eConsent in Beijing hospitals, using video explanations and comprehension checks. Patient satisfaction improved, and the NMPA endorsed the system as compliant. The sponsor later expanded the tool to provincial hospitals, improving recruitment diversity.
Case Study 2: Wearable Integration in Cardiovascular Trial
A cardiovascular trial in Shanghai used wearable devices for remote monitoring of blood pressure and heart rate. Data were transmitted securely to local servers in compliance with PIPL. The trial demonstrated the feasibility of integrating digital health tools into high-risk therapeutic areas.
FAQs
1. Is eConsent legally accepted in China?
Yes, since 2020 the NMPA allows eConsent, provided systems meet requirements for authenticity, audit trails, and patient comprehension.
2. What are the benefits of eConsent?
It improves patient understanding, provides verifiable records for regulators, and enhances accessibility through multimedia explanations.
3. What challenges exist for digital health adoption?
Key challenges include infrastructure gaps in rural areas, patient digital literacy, and compliance with strict data privacy laws.
4. Do ethics committees approve digital health tools?
Yes, all eConsent and digital platforms must be reviewed and approved by ethics committees, often requiring detailed validation documentation.
5. Can wearables be used in Chinese clinical trials?
Yes, but devices must be validated, ethics-approved, and compliant with China’s cybersecurity and data localization requirements.
6. How do digital tools affect recruitment?
They expand recruitment by reaching patients outside Tier-1 hospitals and reduce participant burden, improving trial retention rates.
Conclusion & Call-to-Action
Digital health and eConsent are transforming the way clinical trials are conducted in China, offering opportunities for improved patient engagement, efficiency, and regulatory compliance. While challenges remain in infrastructure, privacy, and ethics oversight, sponsors who adopt digital tools strategically will gain a competitive advantage. Organizations planning trials in China should prioritize early regulatory engagement, system validation, and patient-centered design to fully leverage digital health innovations.